Cretostimogene Grenadenorepvec May be ‘Attractive’ Option for NMIBC


Cretostimogene grenadenorepvec’s efficacy compares favorably with the current nonsurgical standards of care in high-risk, Bacillus Calmette Guerin–unresponsive non-muscle invasive bladder cancer.

Treatment with cretostimogene grenadenorepvec yielded a high complete response (CR) rate in a population of patients diagnosed with high-risk, Bacillus Calmette Guerin (BCG)–unresponsive non-muscle invasive bladder cancer (NMIBC), according to Mark D. Tyson, II, MD, MPH.

In a conversation with CancerNetwork® during the 2023 Society of Urologic Oncology (SUO) Annual Meeting, Tyson, a urologic oncologist of the Department of Urology at Mayo Clinic in Phoenix, Arizona, discussed how cretostimogene appears to demonstrate favorable efficacy in the context of other nonsurgical standards of care in the space such as nadofaragene firadenovec-vncg (Adstiladrin) and pembrolizumab (Keytruda).

Cretostimogene grenadenorepvec was assessed as part of the phase 3 BOND-003 trial (NCT04452591) in patients with high-risk, BCG-unresponsive NMIBC, the interim results of which were read out at the meeting. In a population of 116 patients, investigators reported a CR rate of 75.7% (95% CI, 63.0%-85.0%). Of these responses, 74.4% lasted for a minimum of 6 months. Additionally, the 3-month and 6-month CR rates, respectively, were 68.2% and 63.6%.


This is an interim analysis that compares favorably to the 2 current nonsurgical co-standards, nadofaragene and pembrolizumab. In terms of the complete response rate, the 76% CR rate at any time point compares favorably to the 51% observed with nadofaragene, [as well as] the 41% observed with pembrolizumab. And then the 6-month CR rate of 64% compares favorably with the 41% observed for nadofaragene and the 36% observed for pembrolizumab.

Now, these are interim results; it's really hard to compare across studies. I'm not necessarily saying that cretostimogene monotherapy is better, but I am saying that it does appear to compare favorably, and I do think it will be a really attractive option for many patients looking to preserve their bladder.


Tyson M, Uchio E, Jong-Kil N, et al. First results from BOND-003, a phase 3 study of intravesical cretostimogene grenadenorepvec monotherapy for patients with high-risk BCG- unresponsive non-muscle invasive bladder cancer. Presented at: 2023 Society of Urologic Oncology Annual Meeting; November 28-December 1, 2023; Washington, DC; LBA3396.

Related Videos
The use of a single-port robot may allow for surgically treating more patients with head and neck cancer in a more timely manner, according to Hilary McCrary, MD, MPH.
The AACR Health Disparities Report highlights the changes needed to achieve health equity for patients with cancer.
Robert A. Winn, MD, gives insight into how institutions and community practices can improve access to cancer care.
Patients with KRAS G12C-mutated non–small cell lung cancer who have brain metastases or intolerability of intravenous infusion may be more suitable to receive a small molecule inhibitor compared with chemotherapy, says Sandip P. Patel, MD.
Treatment with sotorasib or adagrasib appears to be more tolerable among patients with KRAS G12C-mutated non–small cell lung cancer compared with docetaxel, according to Sandip Patel, MD.
Notions of blame around smoking may be a prominent factor in patients with lung cancer feeling stigmatized for developing their disease, according to Lisa Carter-Bawa PhD, MPH, APRN, ANP-C, FAAN.
Considering cystectomy in patients with bladder cancer may help with managing the shortage of Bacillus Calmette-Guerin, according to Joshua J. Meeks, MD, PhD, BS.
Anemia in patients who receive talazoparib plus enzalutamide for metastatic castration-resistant prostate cancer appears to be manageable without any compromises in patient-reported outcomes and quality of life.
Patients with locally advanced or metastatic urothelial cancer and visceral disease may particularly benefit from enfortumab vedotin plus pembrolizumab, according to Amanda Nizam, MD.
High-grade adverse effects with zanidatamab plus palbociclib and fulvestrant seem to be uncommon in patients with HER2-positive, hormone receptor–positive, metastatic breast cancer, according to Sara Hurvitz, MD, FACP.
Related Content